Strobopinin

Strobopinin

SCHEMBL4740200

Cc1c(O)cc2c(c1O)C(=O)C[C@@H](c1ccccc1)O2

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABCG2 Q9UNQ0 4/20 1.00
POLB P06746 2/20 1.00
CRHBP P24387 1/20 1.00
CRHR2 Q13324 1/20 1.00
MEN1 O00255 2/20 0.81
KMT2A Q03164 2/20 0.81
APEX1 P27695 1/20 0.81
RECQL P46063 1/20 0.81
CACNA1B Q00975 1/20 0.81
APBA1 Q02410 1/20 0.81
MCL1 Q07820 1/20 0.81
CTDSP1 Q9GZU7 1/20 0.81
L3MBTL1 Q9Y468 1/20 0.81
PLK1 P53350 1/20 0.78
ABCB1 P08183 1/20 0.74
NPC1 O15118 1/20 0.72
RAB9A P51151 1/20 0.72
CYP19A1 P11511 3/20 0.66
CYP3A4 P08684 2/20 0.66
HSD17B10 Q99714 2/20 0.66

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Strobopinin SCHEMBL4740199 1.00 ABCG2 (1.00) ABCG2POLBCRHBPCRHR2MEN1
SCHEMBL24406183 0.90 KMT2A (1.00) ABCG2POLBCRHBPCRHR2MEN1
SCHEMBL29906199 0.90 KMT2A (1.00) ABCG2POLBCRHBPCRHR2MEN1
SCHEMBL29099768 0.90 KMT2A (1.00) ABCG2POLBCRHBPCRHR2MEN1
SCHEMBL12068882 0.88 PLK1 (1.00) ABCG2POLBCRHBPCRHR2MEN1
SCHEMBL31173123 0.88 PLK1 (1.00) ABCG2POLBCRHBPCRHR2MEN1
Strobopinin-7-Methylether SCHEMBL15573726 0.85 ABCG2 (1.00) ABCG2POLBCRHBPCRHR2MEN1
Strobopinin-7-Methylether SCHEMBL15598379 0.85 ABCG2 (1.00) ABCG2POLBCRHBPCRHR2MEN1
Dihydrooroxylin A SCHEMBL31682921 0.84 NPC1 (1.00) ABCG2POLBCRHBPCRHR2MEN1
Dihydrooroxylin A SCHEMBL12067042 0.84 NPC1 (1.00) ABCG2POLBCRHBPCRHR2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11234918-B2 Methods for botanical and/or algae extraction BASF CORPORATION (US) 2022-02-01 US claimed
US-10024846-B2 Methods for treating diet-induced obesity by decreasing or inhibiting P2Y2 purinergic receptor expression or activity THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (US) 2018-07-17 US claimed
EP-2858641-B1 IMPROVED METHODS FOR BOTANICAL AND/OR ALGAE EXTRACTION BASF CORP (US) 2017-09-06 EP claimed
US-20160377598-A1 COMPOSITION AND METHODS FOR THE PREVENTION AND TREATMENT OF DIET-INDUCED OBESITY THE UNITED STATES OF AMERICA AS REPRESENTED BY 2016-12-29 US claimed
US-20150140141-A1 METHODS FOR BOTANICAL AND/OR ALGAE EXTRACTION BASF BEAUTY CARE SOLUTIONS FRANCE SAS (FR) 2015-05-21 US claimed
EP-2858641-A1 IMPROVED METHODS FOR BOTANICAL AND/OR ALGAE EXTRACTION BASF Corporation (US) 2015-04-15 EP claimed
WO-2013184884-A1 IMPROVED METHODS FOR BOTANICAL AND/OR ALGAE EXTRACTION BASF CORPORATION (US) 2013-12-12 WO claimed
US-20240245741-A1 EXTRACTION METHOD USING AN AQUEOUS ALKANEDIOL MINASOLVE SAS (FR) 2024-07-25 US disclosed
EP-4401852-A1 EXTRACTION METHOD USING AN AQUEOUS ALKANEDIOL Minasolve SAS (FR) 2024-07-24 EP disclosed
WO-2023036973-A1 EXTRACTION METHOD USING AN AQUEOUS ALKANEDIOL MINASOLVE SAS (FR) 2023-03-16 WO disclosed
US-11234918-B2 Methods for botanical and/or algae extraction BASF CORPORATION (US) 2022-02-01 US disclosed
US-10981084-B2 Use of coconut water as extraction solvent BASF BEAUTY CARE SOLUTIONS FRANCE SAS (FR) 2021-04-20 US disclosed
US-20190336884-A1 USE OF COCONUT WATER AS EXTRACTION SOLVENT BASF BEAUTY CARE SOLUTIONS FRANCE SAS (FR) 2019-11-07 US disclosed
EP-2858641-B1 IMPROVED METHODS FOR BOTANICAL AND/OR ALGAE EXTRACTION BASF CORP (US) 2017-09-06 EP disclosed
US-20160377598-A1 COMPOSITION AND METHODS FOR THE PREVENTION AND TREATMENT OF DIET-INDUCED OBESITY THE UNITED STATES OF AMERICA AS REPRESENTED BY 2016-12-29 US disclosed
US-20150140141-A1 METHODS FOR BOTANICAL AND/OR ALGAE EXTRACTION BASF BEAUTY CARE SOLUTIONS FRANCE SAS (FR) 2015-05-21 US disclosed
EP-2858641-A1 IMPROVED METHODS FOR BOTANICAL AND/OR ALGAE EXTRACTION BASF Corporation (US) 2015-04-15 EP disclosed
WO-2013184884-A1 IMPROVED METHODS FOR BOTANICAL AND/OR ALGAE EXTRACTION BASF CORPORATION (US) 2013-12-12 WO disclosed
WO-2008100977-A2 CARBAMATES THERAPEUTIC RELEASE AGENTS AS AMIDASE INHIBITORS N.V. ORGANON (NL) 2008-08-21 WO disclosed
EP-0742012-A2 Pharmaceutical composition containing substance inhibiting HSP47 production Kureha Chemical Industry Co., Ltd. (JP) 1996-11-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11234918-B2 Methods for botanical and/or algae extraction ALG1, ALG8, CUTA ABCG2 2792/4885POLB 1138/4885CRHBP 327/4885
US-20150140141-A1 METHODS FOR BOTANICAL AND/OR ALGAE EXTRACTION ALG1, ALG8, CUTA ABCG2 2792/4885POLB 1138/4885CRHBP 327/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.